Company Description

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.

Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Protagenic Therapeutics, Inc.

Country	United States
Founded	1994
IPO Date	Jan 5, 2016
Industry	Biotechnology
Sector	Healthcare
Employees	3

Contact Details

Address: 149 Fifth Avenue, Suite 500 New York, New York 10010 United States
Phone	212 994 8200
Website	protagenic.com

Stock Details

Ticker Symbol	PTIX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001022899
CUSIP Number	74365N103
ISIN Number	US74365N2027
Employer ID	06-1390025
SIC Code	2834

Key Executives

Name	Position
Dr. Garo H. Armen Ph.D.	Co-Founder and Executive Chairman of the Board
Dr. Alexander Kenneth Arrow C.F.A., M.D.	Chief Financial Officer and Secretary
Dr. Andrew Slee Ph.D.	Chief Operating Officer
Dr. Robert Benjamin Stein M.D., Ph.D.	Chief Medical Officer and Director

Latest SEC Filings

Date	Type	Title
Apr 18, 2025	8-K	Current Report
Mar 31, 2025	10-K	Annual Report
Mar 10, 2025	DEF 14A	Other definitive proxy statements
Feb 27, 2025	PRE 14A	Other preliminary proxy statements
Feb 24, 2025	8-K	Current Report
Feb 24, 2025	8-K	Current Report
Feb 14, 2025	SCHEDULE 13G/A	Filing
Jan 29, 2025	8-K	Current Report
Jan 16, 2025	8-K	Current Report
Jan 10, 2025	8-K	Current Report

View All SEC Filings